Maaike H M Oonk1, Brian Slomovitz2, Peter J W Baldwin3, Helena C van Doorn4, Jacobus van der Velden5, Joanne A de Hullu6, Katja N Gaarenstroom7, Brigitte F M Slangen8, Ignace Vergote9, Mats Brännström10, Eleonora B L van Dorst11, Willemien J van Driel12, Ralph H Hermans13, David Nunns14, Martin Widschwendter15, David Nugent16, Cathrine M Holland17, Aarti Sharma18, Paul A DiSilvestro19, Robert Mannel20, Dorry Boll13, David Cibula21, Al Covens22, Diane Provencher23, Ingo B Runnebaum24, David Luesley25, Patricia Ellis26, Timothy J Duncan27, Ming Y Tjiong5, Derek J Cruickshank28, Preben Kjølhede29, Charles F Levenback30, Jiri Bouda31, Katharina E Kieser32, Connie Palle33, Nicola M Spirtos34, David M O'Malley35, Mario M Leitao36, Melissa A Geller37, Kalyan Dhar38, Viren Asher39, Karl Tamussino40, Daniel H Tobias41, Christer Borgfeldt42, Jayanthi S Lea43, Jo Bailey44, Margareta Lood45, Brynhildur Eyjolfsdottir46, Stephen Attard-Montalto47, Krishnansu S Tewari48, Ranjit Manchanda49, Pernille T Jensen50, Par Persson51, Linda Van Le52, Hein Putter7, Geertruida H de Bock1, Bradley J Monk53, Carien L Creutzberg7, Ate G J van der Zee1. 1. University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. 2. Mount Sinai Medical Center, Miami Beach, FL. 3. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom. 4. Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands. 5. Amsterdam University Medical Center, Amsterdam, the Netherlands. 6. Radboud University Medical Center, Nijmegen, the Netherlands. 7. Leiden University Medical Center, Leiden, the Netherlands. 8. Maastricht University Medical Center+, Maastricht, the Netherlands. 9. Leuven Cancer Institute, Leuven, Belgium. 10. Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden. 11. University Medical Center Utrecht, Utrecht, the Netherlands. 12. Center of Gynecological Oncology Amsterdam, The Netherlands Cancer Institute, Amsterdam, the Netherlands. 13. Catharina Ziekenhuis Eindhoven, the Netherlands. 14. Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. 15. UCL EGA Institute for Women's Health, University College London, London, United Kingdom. 16. Leeds Teaching Hospitals NHS Trust, St James' University Hospital, Leeds, United Kingdom. 17. Manchester University NHS Foundation Trust-St Marys Hospital, Manchester, United Kingdom. 18. University Hospital of Wales, Cardiff, United Kingdom. 19. Women and Infants Hospital of Rhode Island, Providence, RI. 20. Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK. 21. First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. 22. University of Toronto, Toronto, Ontario, Canada. 23. CHUM, Université de Montréal, Montréal, Quebec, Canada. 24. Jena University Hospital, Friedrich Schiller University, Jena, Germany. 25. University of Birmingham, Birmingham, United Kingdom. 26. Royal Surrey NHS Foundation Trust, Guildford, United Kingdom. 27. Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom. 28. James Cook University Hospital, South Tees NHS Foundation Trust, Middlesbrough, United Kingdom. 29. Linköping University, Linköping, Sweden. 30. MD Anderson Cancer Center, Houston, TX. 31. University Hospital Pilsen, Charles University, Faculty of Medicine, Pilsen, Czech Republic. 32. Dalhousie University, Halifax, Nova Scotia, Canada. 33. Capio, Part of Ramsey Santé, Hellerup, Denmark. 34. Women's Cancer Center of Nevada, Las Vegas, NV. 35. Ohio State University Comprehensive Cancer Center-James Cancer Hospital, Columbus, OH. 36. Memorial Sloan Kettering Cancer Center, New York, NY. 37. University of Minnesota, Minneapolis, MN. 38. Singleton Hospital, Swansea, United Kingdom. 39. University Hospitals of Derby and Burton, Derby, United Kingdom. 40. Medical University Graz, Graz, Austria. 41. Morristown Medical Center, Morristown, NJ. 42. Skåne University Hospital, Lund University, Lund, Sweden. 43. UT Southwestern Medical Center, Dallas, TX. 44. St Michaels Hospital, Bristol, United Kingdom. 45. Central Hospital Karlstad, Karlstad, Sweden. 46. Oslo University Hospital, Radiumhospitalet, Oslo, Norway. 47. West Kent Cancer Centre, Maidstone Hospital, Maidstone, United Kingdom. 48. UC Irvine Health Medical Center, Orange, CA. 49. Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom. 50. Aarhus University Hospital, Aarhus, Denmark. 51. Uppsala University, Uppsala, Sweden. 52. University of North Carolina, Chapel Hill, NC. 53. St Josephs Hospital and Medical Center, Phoenix, AZ.
Abstract
PURPOSE: The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS: GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS: From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION: Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.
PURPOSE: The Groningen International Study on Sentinel nodes in Vulvar cancer (GROINSS-V)-II investigated whether inguinofemoral radiotherapy is a safe alternative to inguinofemoral lymphadenectomy (IFL) in vulvar cancer patients with a metastatic sentinel node (SN). METHODS: GROINSS-V-II was a prospective multicenter phase-II single-arm treatment trial, including patients with early-stage vulvar cancer (diameter < 4 cm) without signs of lymph node involvement at imaging, who had primary surgical treatment (local excision with SN biopsy). Where the SN was involved (metastasis of any size), inguinofemoral radiotherapy was given (50 Gy). The primary end point was isolated groin recurrence rate at 24 months. Stopping rules were defined for the occurrence of groin recurrences. RESULTS: From December 2005 until October 2016, 1,535 eligible patients were registered. The SN showed metastasis in 322 (21.0%) patients. In June 2010, with 91 SN-positive patients included, the stopping rule was activated because the isolated groin recurrence rate in this group went above our predefined threshold. Among 10 patients with an isolated groin recurrence, nine had SN metastases > 2 mm and/or extracapsular spread. The protocol was amended so that those with SN macrometastases (> 2 mm) underwent standard of care (IFL), whereas patients with SN micrometastases (≤ 2 mm) continued to receive inguinofemoral radiotherapy. Among 160 patients with SN micrometastases, 126 received inguinofemoral radiotherapy, with an ipsilateral isolated groin recurrence rate at 2 years of 1.6%. Among 162 patients with SN macrometastases, the isolated groin recurrence rate at 2 years was 22% in those who underwent radiotherapy, and 6.9% in those who underwent IFL (P = .011). Treatment-related morbidity after radiotherapy was less frequent compared with IFL. CONCLUSION: Inguinofemoral radiotherapy is a safe alternative for IFL in patients with SN micrometastases, with minimal morbidity. For patients with SN macrometastasis, radiotherapy with a total dose of 50 Gy resulted in more isolated groin recurrences compared with IFL.
Authors: Maaike H Oonk; Bettien M van Hemel; Harry Hollema; Joanne A de Hullu; Anca C Ansink; Ignace Vergote; René H Verheijen; Angelo Maggioni; Katja N Gaarenstroom; Peter J Baldwin; Eleonora B van Dorst; Jacobus van der Velden; Ralph H Hermans; Hans W van der Putten; Pierre Drouin; Ingo B Runnebaum; Wim J Sluiter; Ate G van der Zee Journal: Lancet Oncol Date: 2010-05-25 Impact factor: 41.316
Authors: A W Pouwer; F Hinten; J van der Velden; R G V Smolders; B F M Slangen; H J M A A Zijlmans; J IntHout; A G J van der Zee; D Boll; K N Gaarenstroom; H J Arts; J A de Hullu Journal: Gynecol Oncol Date: 2017-07-04 Impact factor: 5.482
Authors: Beant S Gill; Mark E Bernard; Jeff F Lin; Goundappa K Balasubramani; Malolan S Rajagopalan; Paniti Sukumvanich; Thomas C Krivak; Alexander B Olawaiye; Joseph L Kelley; Sushil Beriwal Journal: Gynecol Oncol Date: 2015-04-11 Impact factor: 5.482
Authors: Charles F Levenback; Shamshad Ali; Robert L Coleman; Michael A Gold; Jeffrey M Fowler; Patricia L Judson; Maria C Bell; Koen De Geest; Nick M Spirtos; Ronald K Potkul; Mario M Leitao; Jamie N Bakkum-Gamez; Emma C Rossi; Samuel S Lentz; James J Burke; Linda Van Le; Cornelia L Trimble Journal: J Clin Oncol Date: 2012-07-02 Impact factor: 44.544
Authors: Ate G J Van der Zee; Maaike H Oonk; Joanne A De Hullu; Anca C Ansink; Ignace Vergote; René H Verheijen; Angelo Maggioni; Katja N Gaarenstroom; Peter J Baldwin; Eleonore B Van Dorst; Jacobus Van der Velden; Ralph H Hermans; Hans van der Putten; Pierre Drouin; Achim Schneider; Wim J Sluiter Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: Jay W Carlson; James Kauderer; Alan Hutson; Jeanne Carter; Jane Armer; Suzy Lockwood; Susan Nolte; Bob R Stewart; Lari Wenzel; Joan Walker; Aimee Fleury; Albert Bonebrake; John Soper; Cara Mathews; Oliver Zivanovic; Wm Edward Richards; Annie Tan; David S Alberts; Richard R Barakat Journal: Gynecol Oncol Date: 2019-12-16 Impact factor: 5.482